Findings published in a preprint from a phase I clinical trial on the GLP1glucagon receptor co-agonist NN1177 in adults with overweight or obesity have raised problems with deterioration of glucose tolerance and other safety concerns, despite inducing weight loss, which illustrates the difficulties in getting the agonist balance right during the preclinical development of co-agonist therapies 6,7
Yuan G, Salipante PF, Hudson SD, Gillilan RE, Huang Q, Hatch HW, Shen VK, Grishaev AV, Pabit S, Upadhya R, et al
Smolarek TA, Higgins CV, Amacher DE: Metabolism and cytotoxicity of acetaminophen in hepatocyte cultures from rat, rabbit, dog, and monkey
2.1 Important Pre-Treatment Information Discontinue administration of any iron-containing products prior to administration of INFeD
Mass spectrometry should confirm the identity by matching the measured molecular mass to the expected value of 1419 Da for the GEPPPGKPADDAGLV sequence